» Articles » PMID: 34631699

Differential Expression of the Gene in Pan-Cancer and Its Related Mechanism

Overview
Specialty Cell Biology
Date 2021 Oct 11
PMID 34631699
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Previous studies have revealed the relationship between toll-like receptor 4 () polymorphisms and cancer susceptibility. However, the relationship between and prognosis and immune cell infiltration in pan-cancer patients is still unclear. Through the Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases, the distinct expression of the gene in 24 tumors and normal tissues was analyzed. Univariate Cox proportional hazards regression analysis was used to identify the cancer types whose gene expression was related to prognosis. The relationship between and tumor cell immune invasion was studied. Spearman's rank correlation coefficient was used to analyze the relationship among and immune neoantigens, tumor mutation burden (TMB), microsatellite instability (MSI), DNA repair genes, and DNA methylation. Gene Set Enrichment Analysis (GSEA) was used to identify the tumor-related pathways that the gene was highly expressed in; the expression of the gene was verified with the Human Protein Atlas (HPA) database. Low expression of was associated with an inferior prognosis in kidney renal clear cell carcinoma (KIRC), skin cutaneous melanoma (SKCM), and uterine corpus endometrial carcinoma (UCEC), while high expression was related to a poor prognosis in head and neck squamous cell carcinoma (HNSC), prostate adenocarcinoma (PRAD), stomach adenocarcinoma (STAD), and testicular germ cell tumor (TGCT). The expression of was negatively correlated with the expression of B cells in STAD. The expression of was positively correlated with the infiltration of B cells, CD4 and CD8 T cells, neutrophils, macrophages, and dendritic cells in STAD, KIRC, UCEC, TGCT, and SKCM. The expression of the gene in KIRC, SKCM, STAD, TGCT, and UCEC was highly correlated with inducible T-cell costimulator (), cytotoxic T lymphocyte-associated molecule 4 (), and immune checkpoints. Spearman's rank correlation coefficient showed that the expression of gene was significantly correlated with TMB in STAD and UCEC and was prominently correlated with MSI in TGCT, STAD, and SKCM. The expression of the gene was highly correlated with MLH1, MSH2, and MSH6 in KIRC, SKCM, and STAD. The expression of the gene was remarkably correlated with the methyltransferases DNA methyltransferase 2 (DNMT2) and DNA methyltransferase 3-beta (DNMT3B) in SKCM and STAD. Enrichment analysis showed that was highly expressed in the chemokine signaling pathway and the cell adhesion molecule and cytokine receptor interaction pathway. In summary, the expression of is linked to the prognosis of KIRC, SKCM, STAD, TGCT, and UCEC patients and the level of immune infiltration of CD4, CD8 T cells, macrophages, neutrophils, and dendritic cells.

Citing Articles

MMP9 in pan-cancer and computational study to screen for MMP9 inhibitors.

Ai X, Wang X, Ren T, Li Z, Wu B, Li M Am J Transl Res. 2024; 16(11):7071-7086.

PMID: 39678601 PMC: 11645558. DOI: 10.62347/NXMR6806.


Cytotoxic Effect of Calcineurin B Against Melanoma and Adenocarcinoma Cells In Vitro.

Serrano-Rodriguez M, Araya J, Cortez M, Orrego P Adv Pharmacol Pharm Sci. 2024; 2024:5394494.

PMID: 39640496 PMC: 11620811. DOI: 10.1155/adpp/5394494.


Identification of common core genes and pathways in childhood sepsis and cancer by bioinformatics analysis.

He Y, Ding N, Han M, He H, Xuan L, Gu Z Discov Oncol. 2024; 15(1):749.

PMID: 39636505 PMC: 11621270. DOI: 10.1007/s12672-024-01651-4.


Comprehensive pan-cancer analysis of FUTs family as prognostic and immunity markers based on multi-omics data.

Jia Z, Liao P, Yan B, Lei P Discov Oncol. 2024; 15(1):567.

PMID: 39414693 PMC: 11485001. DOI: 10.1007/s12672-024-01447-6.


Insights into the prognostic value and immunological role of CD74 in pan-cancer.

Liu Z, Chen M, Zheng W, Yuan S, Zhao W Discov Oncol. 2024; 15(1):222.

PMID: 38861249 PMC: 11166624. DOI: 10.1007/s12672-024-01081-2.


References
1.
Szczepanski M, Czystowska M, Szajnik M, Harasymczuk M, Boyiadzis M, Kruk-Zagajewska A . Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 2009; 69(7):3105-13. PMC: 3708458. DOI: 10.1158/0008-5472.CAN-08-3838. View

2.
Feng M, Jiang W, Kim B, Zhang C, Fu Y, Weissman I . Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat Rev Cancer. 2019; 19(10):568-586. PMC: 7002027. DOI: 10.1038/s41568-019-0183-z. View

3.
Beswick E, Johnson J, Saada J, Humen M, House J, Dann S . TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. J Immunol. 2014; 193(5):2218-29. PMC: 4142442. DOI: 10.4049/jimmunol.1203441. View

4.
Baniyash M . Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol. 2006; 16(1):80-8. DOI: 10.1016/j.semcancer.2005.12.002. View

5.
Chen X, Yeong J, Thike A, Bay B, Tan P . Prognostic role of immune infiltrates in breast ductal carcinoma in situ. Breast Cancer Res Treat. 2019; 177(1):17-27. DOI: 10.1007/s10549-019-05272-2. View